Literature DB >> 33574388

Grading system utilising the total score of Oxford classification for predicting renal prognosis in IgA nephropathy.

Yoei Miyabe1, Kazunori Karasawa1, Kenichi Akiyama1, Shota Ogura1, Tomo Takabe1, Naoko Sugiura1, Momoko Seki1, Yuko Iwabuchi1, Norio Hanafusa2, Keiko Uchida1, Kosaku Nitta1, Takahito Moriyama3.   

Abstract

The Oxford classification of IgA nephropathy (IgAN) can evaluate each MEST-C score individually. We analysed a new grading system that utilised the total MEST-C score in predicting renal prognosis. Altogether, 871 IgAN patients were classified into three groups using the new Oxford classification system (O-grade) that utilised the total MEST-C score (O-grade I: 0-1, II: 2-4, and III: 5-7 points), and the 10-year renal prognosis was analysed. The clinical findings became significantly severer with increasing O-grades, and the renal survival rate by the Kaplan-Meier method was 94.1%, 86.9%, and 74.1% for O-grades I, II, and III, respectively. The hazard ratios (HRs) for O-grades II and III with reference to O-grade I were 2.8 (95% confidence interval [CI] 1.3-6.0) and 6.3 (95% CI 2.7-14.5), respectively. In the multivariate analysis, mean arterial pressure and eGFR, proteinuria at the time of biopsy, treatment of corticosteroids/immunosuppressors, and O-grade (HR 1.63; 95% CI 1.11-2.38) were the independent factors predicting renal prognosis. Among the nine groups classified using the O-grade and Japanese clinical-grade, the renal prognosis had an HR of 15.2 (95% CI 3.5-67) in the severest group. The O-grade classified by the total score of the Oxford classification was associated with renal prognosis.

Entities:  

Year:  2021        PMID: 33574388     DOI: 10.1038/s41598-021-82967-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  3 in total

1.  Predicting renal outcome in IgA nephropathy.

Authors:  M G Radford; J V Donadio; E J Bergstralh; J P Grande
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

2.  Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis.

Authors:  E Alamartine; J C Sabatier; F C Berthoux
Journal:  Clin Nephrol       Date:  1990-08       Impact factor: 0.975

3.  Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation.

Authors:  R Katafuchi; Y Kiyoshi; Y Oh; N Uesugi; K Ikeda; T Yanase; S Fujimi
Journal:  Clin Nephrol       Date:  1998-01       Impact factor: 0.975

  3 in total
  6 in total

1.  Correlation between IgAC3 ratio and oxford score in IgA nephropathy.

Authors:  Semahat Karahisar Şirali; Refika Büberci
Journal:  Clin Exp Nephrol       Date:  2022-06-23       Impact factor: 2.617

2.  Arteriolar hyalinosis and renal outcomes in patients with immunoglobulin A nephropathy.

Authors:  Yunzhu Shen; Tangli Xiao; ZhiKai Yu; Yinghui Huang; Ting He; Haiyang Li; Jun Zhang; Jiachuan Xiong; Jinghong Zhao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

3.  Utilizing the MEST score for prognostic staging in IgA nephropathy.

Authors:  Yngvar Lunde Haaskjold; Rune Bjørneklett; Leif Bostad; Lars Sigurd Bostad; Njål Gjærde Lura; Thomas Knoop
Journal:  BMC Nephrol       Date:  2022-01-11       Impact factor: 2.388

4.  A Novel Scoring System Based on Oxford Classification Indicating Steroid Therapy Use for IgA Nephropathy.

Authors:  Shusaku Itami; Takahito Moriyama; Yoei Miyabe; Kazunori Karasawa; Kosaku Nitta
Journal:  Kidney Int Rep       Date:  2021-10-14

Review 5.  New Insights into the Treatment of Glomerular Diseases: When Mechanisms Become Vivid.

Authors:  Da-Wei Lin; Cheng-Chih Chang; Yung-Chien Hsu; Chun-Liang Lin
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

6.  Relationship between Traditional Chinese Medicine Syndrome Elements and Prognosis of Patients with IgA Nephropathy.

Authors:  Jianghua Ke; Shuwei Duan; Linchang Liu; Zhiwei Yin; Shuang Li; Yujing Ke; Jin Yao; Ying Zheng; Weiguang Zhang; Yilun Qu; Ping Li; Zheyi Dong; Xiangmei Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-30       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.